News | May 24, 2025
CPHI & PMEC China sees surge in international attendance
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
Record international participation reflects renewed momentum in pharma manufacturing and global sourcing, as easing tariffs fuel growth
3SBio will receive an upfront payment of $1.25 billion and is eligible to receive milestone payments associated with certain development, regulatory and commercial milestones up to $4.8 billion
This approval authorizes the company to export Ibuprofen to the Chinese markets
This marks a significant milestone in Morepen’s strategic entry into one of the world’s largest pharmaceutical markets
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari and Suzhou
Our China operations continue under the leadership of the current General Manager of AstraZeneca China
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Subscribe To Our Newsletter & Stay Updated
